2seventy bio, Inc. (TSVT)
2seventy bio, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Cambridge, MA, US. The stock last traded at $5.00, up 0.00% on the session, giving a market capitalisation of $266.1M. On trailing twelve-month figures it carries a trailing P/E of -4.55, a net margin of -151.2%. Its beta of 1.05 implies it has historically moved more than the broad market.
2seventy bio, Inc. operates as a biotechnology firm specializing in cell and gene therapies, with a primary mission to discover, develop, and commercialize advanced cancer treatments within the U.S. Its pipeline notably includes idecabtagene vicleucel, marketed as ide-cel or Abecma, and bb21217, both of which are CAR-T cell therapeutic candidates specifically designed to address multiple myeloma. The company also maintains a strategic partnership with Bristol-Myers Squibb Company. Founded in 2021, its corporate headquarters are situated in Cambridge, Massachusetts.
2seventy bio, Inc. is most often compared with the following Healthcare names: